دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Precision in psychiatry—A roadmap to translate neurobiological measures to the clinic
Mayuresh S. Korgaonkar
doi : 10.1111/bdi.13160
Volume 23, Issue 8 p. 747-750
The rise and fall of cognitive-behavioral approaches to the treatment of bipolar disorder: A critical overview from a quaternary prevention perspective
Cecilia Samamé
doi : 10.1111/bdi.13146
Volume 23, Issue 8 p. 751-753
Efficacy and acceptability of pharmacotherapy for comorbid anxiety symptoms in bipolar disorder: A systematic review and meta-analysis
Clare Cullen,Nils Kappelmann,Madeha Umer,Ali Abdolizadeh,Muhammad Omair Husain,Sarah Bonato,Gaurav Sharma,Siqi Xue,Abigail Ortiz,Stefan M. Kloiber,Benoit H. Mulsant,Muhammad I. Husain
doi : 10.1111/bdi.13125
Volume 23, Issue 8 p. 754-766
Anxiety symptoms are highly prevalent among individuals with bipolar disorder (BD) but there is little guidance on pharmacotherapy for these symptoms. The objective of this systematic review and meta-analysis was to evaluate the available evidence for pharmacotherapy of comorbid anxiety symptoms in BD.
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations
Lakshmi N. Yatham,Trisha Chakrabarty,David J. Bond,Ayal Schaffer,Serge Beaulieu,Sagar V. Parikh,Roger S. McIntyre,Roumen V. Milev,Martin Alda,Gustavo Vazquez,Arun V. Ravindran,Benicio N. Frey,Verinder Sharma,Benjamin I. Goldstein,Soham Rej,Claire O’Donovan,Valerie Tourjman,Jan-Marie Kozicky,Marcia Kauer-Sant’Anna,Gin Malhi,Trisha Suppes,Eduard Vieta,Flavio Kapczinski,Shigenobu Kanba,Raymond W. Lam,Sidney H. Kennedy,Joseph Calabrese,Michael Berk,Robert Post
doi : 10.1111/bdi.13135
Volume 23, Issue 8 p. 767-788
The 2018 Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) guidelines provided clinicians with pragmatic treatment recommendations for bipolar disorder (BD). While these guidelines included commentary on how mixed features may direct treatment selection, specific recommendations were not provided—a critical gap which the current update aims to address.
Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials
Taro Kishi,Kenji Sakuma,Makoto Okuya,Yuki Matsuda,Satoru Esumi,Yasuhiko Hashimoto,Masakazu Hatano,Nobumi Miyake,Itaru Miura,Kazuo Mishima,Nakao Iwata
doi : 10.1111/bdi.13053
Volume 23, Issue 8 p. 789-800
A systematic review and meta-analysis of double-blind, randomized placebo-controlled trials were conducted to examine how soon an increase in recurrence risk could be observed among bipolar I disorder (BDI) patients who were clinically stable with the combination therapy of mood stabilizers with second-generation antipsychotics (SGA+MS) treatment following second-generation antipsychotics discontinuation (i.e., MS alone) compared with SGA+MS maintenance.
Reduced white matter microstructure in bipolar disorder with and without psychosis
Jennifer A. Brown,Brooke S. Jackson,Courtney R. Burton,Jennifer E. Hoy,John A. Sweeney,Godfrey D. Pearlson,Matcheri S. Keshavan,Sarah S. Keedy,Elliot S. Gershon,Carol A. Tamminga,Brett A. Clementz,Jennifer E. McDowell
doi : 10.1111/bdi.13055
Volume 23, Issue 8 p. 801-809
Affective and psychotic features overlap considerably in bipolar I disorder, complicating efforts to determine its etiology and develop targeted treatments. In order to clarify whether mechanisms are similar or divergent for bipolar disorder with psychosis (BDP) and bipolar disorder with no psychosis (BDNP), neurobiological profiles for both the groups must first be established. This study examines white matter structure in the BDP and BDNP groups, in an effort to identify portions of white matter that may differ between the bipolar and healthy groups or between the bipolar subgroups themselves.
A digital self-report survey of mood for bipolar disorder
Tijana Sagorac Gruichich,Juan Camilo David Gomez,Gabriel Zayas-Cabán,Melvin G. McInnis,Amy L. Cochran
doi : 10.1111/bdi.13058
Volume 23, Issue 8 p. 810-820
Bipolar disorder (BP) is commonly researched in digital settings. As a result, standardized digital tools are needed to measure mood. We sought to validate a new survey that is brief, validated in digital form, and able to separately measure manic and depressive severity.
Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study
Yian Lin,Adam X. Maihofer,Emma Stapp,Megan Ritchey,Ney Alliey-Rodriguez,Amit Anand,Yokesh Balaraman,Wade H. Berrettini,Holli Bertram,Abesh Bhattacharjee,Cynthia V. Calkin,Carla Conroy,William Coryell,Nicole D'Arcangelo,Anna DeModena,Joanna M. Biernacka,Carrie Fisher,Nicole Frazier,Mark Frye,Keming Gao,Julie Garnham,Elliot Gershon,Kara Glazer,Fernando S. Goes,Toyomi Goto,Elizabeth Karberg,Gloria Harrington,Petter Jakobsen,Masoud Kamali,Marisa Kelly,Susan G. Leckband,Falk W. Lohoff,Andrea Stautland,Michael J. McCarthy,Melvin G. McInnis,Francis Mondimore,Gunnar Morken,John I. Nurnberger,Ketil J. Oedegaard,Vigdis Elin Giever Syrstad,Kelly Ryan,Martha Schinagle,Helle Schoeyen,Ole A. Andreassen,Marth Shaw,Paul D. Shilling,Claire Slaney,Bruce Tarwater,Joseph R. Calabrese,Martin Alda,Caroline M. Nievergelt,Peter P. Zandi,John R. Kelsoe
doi : 10.1111/bdi.13078
Volume 23, Issue 8 p. 821-831
Lithium is regarded as a first-line treatment for bipolar disorder (BD), but partial response and non-response commonly occurs. There exists a need to identify lithium non-responders prior to initiating treatment. The Pharmacogenomics of Bipolar Disorder (PGBD) Study was designed to identify predictors of lithium response.
Should medications with little or no efficacy be prescribed when treating bipolar disorder?
Takeshi Terao
doi : 10.1111/bdi.13141
Volume 23, Issue 8 p. 832-833
A commentary on youth onset bipolar disorder
Manpreet K. Singh,Robert M. Post,David J. Miklowitz,Boris Birmaher,Eric Youngstrom,Benjamin Goldstein,Cesar Soutullo,David Axelson,Kiki D. Chang,Melissa P. DelBello
doi : 10.1111/bdi.13148
Volume 23, Issue 8 p. 834-837
Questions in Psychiatry (QuiP): Using your Apple all day, might keep the doctor away?
Gin S. Malhi,Erica Bell
doi : 10.1111/bdi.13157
Volume 23, Issue 8 p. 838-841
Cigarette smokers with a mood symptom history enrolled in a physical activity trial
Alexandra K. Gold,Evan A. Albury,Audrey Stromberg,Noah J. French,Amy T. Peters,Douglas Katz,Andrew A. Nierenberg,Louisa G. Sylvia
doi : 10.1111/bdi.13140
Volume 23, Issue 8 p. 842-843
Symptomatic improvement of acute mania associated with a single session of electroconvulsive therapy: A proposed concept of neuroversion
Amílcar Silva-dos-Santos,Miguel Bruno Sales,Diana Venda
doi : 10.1111/bdi.13107
Volume 23, Issue 8 p. 844-846
First manic episode following COVID-19 infection
Jin Hong Park,Megan Kummerlowe,Manuel Gardea Resendez,Nicolas A. Nuñez,Ammar Almorsy,Mark A. Frye
doi : 10.1111/bdi.13123
Volume 23, Issue 8 p. 847-849
The importance of countertransference in the clinical care of individuals during acute phases of bipolar disorder
Andrew A. B. Shaw,Rachel Ashby,Fabiano A. Gomes,Elisa Brietzke
doi : 10.1111/bdi.13111
Volume 23, Issue 8 p. 850-851
